VK 2735
Alternative Names: VK-2735Latest Information Update: 26 Jul 2024
At a glance
- Originator Viking Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Non-alcoholic steatohepatitis
- Preclinical Diabetes mellitus